After the high-calorie regimen had been in place for 24 weeks (Study 1), and mice exhibited impaired glucose tolerance and hyperinsulinemia, we used the potent Nrf2 activator TBE-3132, 33 (Figure 1) to test if it could improve insulin sensitivity and glucose homeostasis, and mitigate NASH in the liver. This evidence concerns the gene NFE2L2 and metabolic dysfunction-associated steatohepatitis.